RYO OGAWA

RYO OGAWA


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2023 in Annals of Surgery
Verified
Journal Article
Open access
Ryota MatsuiRyota Matsui
Ryota Matsui
MSMasano Sagawa
Masano Sagawa
ASAkihiko Sano
Akihiko Sano
MSMakoto Sakai
Makoto Sakai
SHShin-ichiro Hiraoka
Shin-ichiro Hiraoka
JKJoji Kotani
Joji Kotani
Objective: To clarify whether perioperative immunonutrition is effective in adult patients with or without malnutrition undergoing elective surgery for head and neck (HAN) or gastrointestinal (GI) cancers. Background: It is important to avoid postoperative complications in patients with cancer as they can compromise clinical outcomes. There is no consensus on the efficacy of perioperative immunonutrition in patients with or without malnutrition undergoing HAN or GI cancer surgery. Materials and Methods: We searched MEDLINE (PubMed), MEDLINE (OVID), EMBASE, Cochrane Central Register of Controlled Trials, Web of Science Core Selection, and Emcare from 1981 to 2022 using search terms related to immunonutrition and HAN or GI cancer. We included randomized controlled trials. Intervention was defined as immunonutritional therapy including arginine, n-3 omega fatty acids, or glutamine during the perioperative period. The control was defined as standard nutritional therapy. The primary outcomes were total postoperative and infectious complications, defined as events with a Clavien–Dindo classification grade ≥ II that occurred within 30 days after surgery. Results: Of the 4825 patients from 48 included studies, 19 had upper GI cancer, 9 had lower, and 8 had mixed cancer, whereas 12 had HAN cancers. Immunonutrition reduced the total postoperative complications (relative risk ratio: 0.78; 95% CI, 0.66–0.93; certainty of evidence: high) and infectious complications (relative risk ratio: 0.71; 95% CI, 0.61–0.82; certainty of evidence: high) compared with standard nutritional therapy. Conclusions: Nutritional intervention with perioperative immunonutrition in patients with HAN and GI cancers significantly reduced total postoperative complications and infectious complications.

3 March 2021 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
MKMasaaki Kodama
Masaaki Kodama
TOTadayoshi Okimoto
Tadayoshi Okimoto
Kazuhiro MizukamiKazuhiro Mizukami
Kazuhiro Mizukami
YHYuka Hirashita
Yuka Hirashita
YWYasuhiro Wada
Yasuhiro Wada
Kazunari MurakamiKazunari Murakami
Kazunari Murakami

1 January 2012 in Journal of Clinical Biochemistry and Nutrition
Verified
Journal Article
Open access
PDF file
Kazuhiro MizukamiKazuhiro Mizukami
Kazuhiro Mizukami
Kazunari MurakamiKazunari Murakami
Kazunari Murakami
YHYuka Hirashita
Yuka Hirashita
AHAkari Hisamatsu
Akari Hisamatsu
RORYO OGAWA
RYO OGAWA
TFToshio Fujioka
Toshio Fujioka
Gastrointestinal symptoms are a problematic issue for patients who take low-dose aspirin for long time. We conducted a pilot study to investigate the efficacy of combination therapy with proton pump inhibitor and rebamipide. This was a prospective, randomized, double-blind, placebo-controlled cross-over study. All the subjects received aspirin 100 mg and omeprazole 20 mg. The subjects were divided into two groups and received either rebamipide 300 mg or placebo, which was prescribed for 4 weeks. The subjects were instructed to record their gastrointestinal symptom rating scale before the study and 1 and 4 weeks after beginning the protocol. These scores of the groups were compared before and after the treatment to evaluate the severity of their symptoms and the number of symptom items present in each group. For the subjects receiving rebamipide, the total prevalence of lower gastrointestinal symptoms was significantly different from the placebo group (p=0.0093) at week 4. No troublesome symptoms were observed in the rebamipide group. Inconclusion, the administration of rebamipide prevented the occurrence of troublesome symptoms, especially lower gastrointestinal symptoms, in patients taking aspirin and omeprazole. Rebamipide is a candidate drug for combination therapy with proton pump inhibitors to prevent low-dose aspirin-induced gastrointestinal symptoms.

1 January 2002 in Journal of Nippon Medical School
Verified
Journal Article
Open access
PDF file
NSNorihito Suzuki
Norihito Suzuki
ASAtsuhiro Sakamoto
Atsuhiro Sakamoto
RORYO OGAWA
RYO OGAWA
Overproduction of nitric oxide (NO) by inducible NO synthase (iNOS) plays a role in the pathophysiology of septic shock. The depression of cardiac contractility in such situations is mediated by proinflammatory cytokines, including interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α). The effects of two NOS inhibitors with different isoform selectivity were compared in isolated working rat hearts. The depression of contractility by IL-1β and TNF-α was prevented by administration of a nonselective nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester (L-NAME) or an inhibitor of inducible nitric oxide synthase, L-canavanine. In contrast, when L-NAME was administered in the absence of IL-1β and TNF-α, it depressed contractility over the 2h perfusion period by significantly reducing coronary flow. These results support current thinking that the depression of myocardial function by IL-1β and TNF-α is mediated, at least in part, by an intracardiac increase in inducible nitric oxide synthase, and that in contrast to L-NAME, the decline in coronary conductance seen in cytokine-treated is not prevented by L-canavanine hearts. L-canavanine shows selective inhibition of inducible nitric oxide synthase unlike the vasopressor action of L-NAME in cytokine-treated hearts.

23 February 2022 in Surgery Today
Verified
Journal Article
Closed access
PDF file
SHShunsuke Hayakawa
Shunsuke Hayakawa
RORYO OGAWA
RYO OGAWA
SUShuhei Ueno
Shuhei Ueno
SISunao Ito
Sunao Ito
TOTomotaka Okubo
Tomotaka Okubo
STShuji Takiguchi
Shuji Takiguchi

23 December 2021 in Diseases of the Esophagus
Verified
Journal Article
Closed access
PDF file
NUNaoto Ujiie
Naoto Ujiie
HSHiroki Sato
Hiroki Sato
MFMary Raina Angeli Fujiyoshi
Mary Raina Angeli Fujiyoshi
STShinwa Tanaka
Shinwa Tanaka
HSHironari Shiwaku
Hironari Shiwaku
HIHaruhiro Inoue
Haruhiro Inoue
Geriatric patients with existing studies on the safety and efficacy of peroral endoscopic myotomy (POEM) for achalasia involve small sample sizes and single institutions. However, multi-center, large-scale data analyses are lacking. The study aimed to clarify the characteristics of geriatric patients with esophageal motility disorders (EMDs) and determine the procedure-related outcomes and clinical course following POEM. This cohort study included 2,735 patients with EMDs who were treated at seven Japanese facilities between 2010 and 2019. The patients’ characteristics and post-POEM clinical courses were compared between the geriatric (age ≥ 75 years; n = 321) and non-geriatric (age < 75 years; n = 2,414) groups. Compared with the non-geriatric group, the geriatric group had higher American Society of Anesthesiologists physical status scores; more recurrent cases; lower incidence of chest pain; and higher incidence of type III achalasia, distal esophageal spasm, and Jackhammer esophagus. Furthermore, the incidence of sigmoid esophagus was higher, although esophageal dilation was not severe in this group. POEM was safe and effective for geriatric patients with treatment-naïve and recurrent EMDs. Furthermore, compared with the non-geriatric group, the geriatric group had lower post-POEM Eckardt scores, fewer complaints of refractory chest pain, and a lower incidence rate of post-POEM reflux esophagitis. Geriatric patients are characterized by worse clinical conditions, more spastic disorders, and greater disease progression of EMDs, which are also the indications for minimally invasive POEM. POEM is more beneficial in geriatric patients as it has lowering symptom scores and incidence rates of reflux esophagitis.